Nerve sheath tumorile and epithelioid tu Gliomas Glioneuronal tumors c2.LEIN MIDBRAIN MARKERS c2.ZHOU INFLAMMATORY RESPONSE LIVE DN c2.RIGGI EWING SARCOMA PROGENITOR UP c2.WP LIPID PARTICLES COMPOSITION c2.SMID BREAST CANCER LUMINAL A DN c2.REACTOME G ALPHA I SIGNALLING EVENTS c2.YAGUE PRETUMOR DRUG RESISTANCE UP c2.WP PRIMARY OVARIAN INSUFFICIENCY c2.TIAN TNF SIGNALING VIA NFKB c2. HAN THE SIGNALING VIA HERB c2.MIZUKAMI HYPOXIA UP c2.HO LIVER CANCER VASCULAR INVASION c2.REACTOME ACTIVATION OF PPARGC1A PGC 1ALPHA BY PHOSPHORYLATION c2.REACTOME METABOLISM OF VITAMINS AND COFACTORS c2.WP DNA REPLICATION c2.WP WHITE FAT CELL DIFFERENTIATION c2.WP OMEGA6FATTY ACIDS IN SENESCENCE c2.WILENSKY RESPONSE TO DARAPLADIB c2.GAVIN FOXP3 TARGETS CLUSTER P4 c2.KEGG MEDICUS ENV FACTOR DCE TO DNA ADDUCTS c2.REACTOME NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY c2.RUIZ TNC TARGETS DN c2.REACTOME THE FATTY ACID CYCLING MODEL c2.REACTOME ADENYLATE CYCLASE ACTIVATING PATHWAY c2.WP FEMALE STEROID HORMONES IN CARDIOMYOCYTE ENERGY METABOLISM c2.ZHOU INFLAMMATORY RESPONSE FIMA UP c2.SHIN B CELL LYMPHOMA CLUSTER 8 c2.REACTOME INDUCTION OF CELL CELL FUSION c2.REACTOME PHASE 0 RAPID DEPOLARISATION c2.LIN NPAS4 TARGETS DN c2.YIH RESPONSE TO ARSENITE C5 c2.BLANCO MELO COVID19 SARS COV 2 INFECTION A594 ACE2 EXPRESSING CELLS UP c2.HOLLEMAN DAUNORUBICIN ALL UP c2.KEGG MEDICUS REFERENCE CORE NER REACTION c2.NAKAYAMA SOFT TISSUE TUMORS PCA1 DN c2.PID EPHA FWDPATHWAY c2.BRUINS UVC RESPONSE VIA TP53 GROUP C c2.WP TOLLLIKE RECEPTOR SIGNALING RELATED TO MYD88 c2.REACTOME BIOSYNTHESIS OF THE N GLYCAN PRECURSOR DOLICHOL LIPID LINKED OLIGOSACCHARIDE LLO AND TRANSFER TO A NASCENT PROTEIN c2.WP CELLTYPE DEPENDENT SELECTIVITY OF CCK2R SIGNALING c2.BROWNE HCMV INFECTION 8HR DN c2.LI ESTROGENE BIDIRECTIONAL E2 RESPONSE c2.WP TRYPTOPHAN METABOLISM c2.SATO SILENCED BY METHYLATION IN PANCREATIC CANCER 1 c2.FUJIWARA PARK2 IN LIVER CANCER UP c2.REACTOME DRUG ADME c2.WP MARKERS OF KIDNEY CELL LINEAGE c2.MIKKELSEN DEDIFFERENTIATED STATE UP c2.WP NANOMATERIAL INDUCED APOPTOSIS c2.STEIN ESRRA TARGETS RESPONSIVE TO ESTROGEN DN c2.UNTERMAN IPF VS CTRL CD4T DN c2.KEGG MEDICUS REFERENCE AUTOPHAGY VESICLE NUCLEATION ELONGATION MATURATION E3 UBIQUITIN LIGASE MALIN c2.BIOCARTA CREM PATHWAY c2.REACTOME DEGRADATION OF CYSTEINE AND HOMOCYSTEINE c2.REACTOME AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE c2.WP COMPLEMENT AND COAGULATION CASCADES
c2.REACTOME DEFECTS OF CONTACT ACTIVATION SYSTEM CAS AND KALLIKREIN KININ SYSTEM KKS c2.REACTOME SYNTHESIS OF SUBSTRATES IN N GLYCAN BIOSYTHESIS c2.TRAYNOR RETT SYNDROM UP c2.NADELLA PRKAR1A TARGETS DN c2.WP CARDIAC PROGENITOR DIFFERENTIATION
c2.POS RESPONSE TO HISTAMINE DN
c2.SMID BREAST CANCER RELAPSE IN BRAIN DN
c2.YANG BREAST CANCER ESR1 LASER UP
c2.WP DNA IRDAMAGE AND CELLULAR RESPONSE VIA ATR
c2.WP VITAMIN B12 METABOLISM c2.WP MITOCHONDRIAL IMMUNE RESPONSE TO SARSCOV2 c2.OHM METHYLATED IN ADULT CANCERS c2.WP CHOLESTASIS c2.FREDERICK PRKCI TARGETS c2.GHANDHI BYSTANDER IRRADIATION DN c2.WP NUCLEAR RECEPTORS c2.KEGG PRIMARY BILE ACID BIOSYNTHESIS c2.ACEVEDO LIVER CANCER WITH H3K9ME3 UP c2.BIOCARTA FXR PATHWAY c2.ZHU CMV 8 HR UP c2.REACTOME ARACHIDONIC ACID METABOLISM c2.MATZUK IMPLANTATION AND UTERINE c2.SOUCEK MYC TARGETS c2.LI PROSTATE CANCER EPIGENETIC c2.SCIAN CELL CYCLE TARGETS OF TP53 AND TP73 DN c2.WP GENES CONTROLLING NEPHROGENESIS c2.WP CHRONIC HYPERGLYCEMIA IMPAIRMENT OF NEURON FUNCTION c2.WARTERS RESPONSE TO IR SKIN c2.WP GANGLIO SERIES SPHINGOLIPID METABOLISM c2.KEGG HEDGEHOG SIGNALING PATHWAY c2.VECCHI GASTRIC CANCER EARLY DN c2.WP CELL DIFFERENTIATION EXPANDED INDEX c2.ZHANG GATA6 TARGETS DN c2.KEGG MEDICUS REFERENCE CHONDROITIN SULFATE BIOSYNTHESIS c2.SATO SILENCED EPIGENETICALLY IN PANCREATIC CANCER c2.WP MYD88 DISTINCT INPUTOUTPUT PATHWAY c2.PEDRIOLI MIR31 TARGETS UP c2.REACTOME NEGATIVE REGULATION OF ACTIVITY OF TFAP2 AP 2 FAMILY TRANSCRIPTION FACTORS c2.GRANDVAUX IRF3 TARGETS UP c2.REACTOME DIFFERENTIATION OF KERATINOCYTES IN INTERFOLLICULAR EPIDERMIS IN MAMMALIAN SKIN c2.REACTOME EXTENSION OF TELOMERES c2.KEGG MEDICUS REFERENCE LEUCINE DEGRADATION c2.YOKOE CANCER TESTIS ANTIGENS c2.TESAR ALK TARGETS EPISC 4D UP c2.LI CYTIDINE ANALOG PATHWAY c2.WP BIOTIN METABOLISM INCLUDING IMDS c2.GAUSSMANN MLL AF4 FUSION TARGETS D UP c2.FONTAINE THYROID TUMOR UNCERTAIN MALIGNANCY DN c2.CHYLA CBFA2T3 TARGETS UP c2.WILLIAMS ESR1 TARGETS UP c2.MASRI RESISTANCE TO TAMOXIFEN AND AROMATASE INHIBITORS UP c2.SATO SILENCED BY DEACETYLATION IN PANCREATIC CANCER c2.RAMJAUN APOPTOSIS BY TGFB1 VIA MAPK1 DN c2.NABA MATRISOM c2.ACEVEDO LIVER CANCER WITH H3K27ME3 UF c2.WP VITAMIN D RECEPTOR PATHWAY c2.REACTOME HDL REMODELING c2.REACTOME SLC MEDIATED TRANSMEMBRANE TRANSPORT c2.WP COMPLEMENT ACTIVATION c2.FIGUEROA AML METHYLATION CLUSTER 7 DN c2.PETRETTO BLOOD PRESSURE UP c2.BOYERINAS ONCOFETAL TARGETS OF LET7A1 c2.KEGG PHENYLALANINE METABOLISM c2.REACTOME BH3 ONLY PROTEINS ASSOCIATE WITH AND INACTIVATE ANTI APOPTOTIC BCL 2 MEMBERS c2.BYSTRYKH HEMATOPOIESIS STEM CELL FGF3 c2.MUELLER COMMON TARGETS OF AML FUSIONS DN c2.LEE LIVER CANCER E2F1 DN c2.CERVERA SDHB TARGETS 1 UP c2.KEGG MEDICUS REFERENCE CGAS STING SIGNALING PATHWAY c2.KEGG CALCIUM SIGNALING PATHWAY c2.MCGARVEY SILENCED BY METHYLATION IN COLON CANCER
c2.RAFFEL VEGFA TARGETS DN c2.NAKAJIMA EOSINOPHIL c2.BOYAULT LIVER CANCER SUBCLASS G23 DN c2.CHO NR4A1 TARGETS c2.DAUER STAT3 TARGETS DN c2.SMID BREAST CANCER LUMINAL B UP c2.KEGG MEDICUS REFERENCE WNT SIGNALING MODULATION SOST LRP4 0 0 c2.MANNE COVID19 NONICU VS HEALTHY DONOR PLATELETS UP c2.LEE LIVER CANCER SURVIVAL UP c2.REACTOME LYSINE CATABOLISM c2. YAUCH HEDGEHOG SIGNALING PARACRINE UP c2.DOANE BREAST CANCER ESR1 DN c2.NIKOLSKY BREAST CANCER 22Q13 AMPLICON c2.VANDESLUIS COMMD1 TARGETS GROUP 4 UP c2.RIZ ERYTHROID DIFFERENTIATION 6HR c2.KEGG ABC TRANSPORTERS c2.KEGG MEDICUS VARIANT FZD7 OVEREXPRESSION TO WNT SIGNALING PATHWAY c2.WP DENGUE2 INTERACTIONS WITH COMPLEMENT AND COAGULATION CASCADES c2.KEGG MEDICUS REFERENCE ATR P21 CELL CYCLE G2 M c2.KEGG MEDICUS REFERENCE TLR3 IRF7 SIGNALING PATHWAY c2.REACTOME SYNTHESIS OF DOLICHYL PHOSPHATE c2.HECKER IFNB1 TARGETS c2.KEGG MISMATCH REPAIR c2.WINTER HYPOXIA DN c2.SANDERSON PPARA TARGETS c2.CAIRO LIVER DEVELOPMENT DN c2.REACTOME G ALPHA S SIGNALLING EVENTS c2.XU HGF TARGETS INDUCED BY AKT1 48HR UP c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 3D UP c2.WP TYROBP CAUSAL NETWORK IN MICROGLIA c2.REACTOME TRNA PROCESSING c2.REACTOME BIOLOGICAL OXIDATIONS c2.UNTERMAN PROGRESSIVE VS STABLE IPF MONOCYTE DN c2.VERNELL RETINOBLASTOMA PATHWAY UP c2.KEGG MEDICUS REFERENCE GF RTK PI3K SIGNALING PATHWAY c2.HOWLIN CITED1 TARGETS 2 DN c2.BOQUEST STEM CELL DN c2.REACTOME FORMATION OF THE ANTERIOR NEURAL PLATE c2.YU BAP1 TARGETS c2.GENTLES LEUKEMIC STEM CELL UP c2.LIN SILENCED BY TUMOR MICROENVIRONMENT c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 25 c2.REACTOME SULFUR AMINO ACID METABOLISM c2.REACTOME TRIGLYCERIDE BIOSYNTHESIS c2.BENPORATH ES CORE NINE c2.JAATINEN HEMATOPOIETIC STEM CELL DN c2.FUKUSHIMA TNFSF11 TARGETS c2.REACTOME TFAP2 AP 2 FAMILY REGULATES TRANSCRIPTION OF GROWTH FACTORS AND THEIR RECEPTORS c2.KAMIKUBO MYELOID CEBPA NETWORK c2.SCHAEFFER SOX9 TARGETS IN PROSTATE DEVELOPMENT UP c2.WP MAMMALIAN DISORDER OF SEXUAL DEVELOPMENT c2.REACTOME FGFR1C LIGAND BINDING AND ACTIVATION c2.BIOCARTA LYM PATHWAY c2.SANA RESPONSE TO IFNG UP c2.REACTOME RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN WNT SIGNALING c2.MATZUK OVULATION c2.LI ESTROGENE T47D E2 RESPONSE DN c2.GAUSSMANN MLL AF4 FUSION TARGETS C DN c2.PID NFAT TFPATHWAY c2.VALK AML WITH 11Q23 REARRANGED c2.REACTOME CARDIAC CONDUCTION c2.REACTOME TRNA AMINOACYLATION
c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS BLUE DN
c2.WP GENES RELATED TO PRIMARY CILIUM DEVELOPMENT BASED ON CRISPR c2.REACTOME TRANSPORT OF NUCLEOTIDE SUGARS c2.FUNG IL2 TARGETS WITH STAT5 BINDING SITES c2.WHITE NEUROBLASTOMA WITH 1P36.3 DELETION c2.REACTOME METABOLISM OF PORPHYRINS c2.REACTOME REGULATION OF GENE EXPRESSION IN BETA CELLS c2.REACTOME GLUTATHIONE CONJUGATION c2.REACTOME BETA OXIDATION OF VERY LONG CHAIN FATTY ACIDS c2.MOREIRA RESPONSE TO TSA DN c2.KEGG MEDICUS VARIANT EML4 ALK FUSION KINASE TO JAK STAT SIGNALING PATHWAY c2.REACTOME HEME BIOSYNTHESIS c2.BLANCO MELO COVID19 SARS COV 2 LOW MOI INFECTION A594 ACE2 EXPRESSING CELLS DN c2.REACTOME DISEASES ASSOCIATED WITH O GLYCOSYLATION OF PROTEINS
c2.HAMAI APOPTOSIS VIA TRAIL DN
c2.CARRILLOREIXACH 14Q32OVEREXPRESSION IN HEPATOBLASTOMA c2.REACTOME FORMATION OF FIBRIN CLOT CLOTTING CASCADE c2.MARSON FOXP3 TARGETS STIMULATED UP c2.KEGG MEDICUS REFERENCE MODIFYING OF CONDENSIN II SUBUNITS c2.REACTOME NR1H2 NR1H3 REGULATE GENE EXPRESSION LINKED TO GLUCONEOGENESIS
c2.REACTOME G ALPHA Q SIGNALLING EVENTS
c2.CROONQUIST IL6 DEPRIVATION UP c2.SATO SILENCED BY METHYLATION IN PANCREATIC CANCER 2 c2.REACTOME O GLYCOSYLATION OF TSR DOMAIN CONTAINING PROTEINS c2.CHIANG LIVER CANCER SUBCLASS INTERFERON UP c2.KEGG TAURINE AND HYPOTAURINE METABOLISM c2.HOEGERKORP CD44 TARGETS TEMPORAL UP c2.SAKAI CHRONIC HEPATITIS VS LIVER CANCER DN c2.KEGG MEDICUS REFERENCE ATR SIGNALING c2.KEGG MEDICUS PATHOGEN HIV TAT TO TLR2 4 NFKB SIGNALING PATHWAY c2.REACTOME PROCESSIVE SYNTHESIS ON THE C STRAND OF THE TELOMERE c2.XIE ST HSC S1PR3 OE UP c2.WP BENZENE METABOLISM c2.WANG RESPONSE TO BEXAROTENE UP c2.BHAT ESR1 TARGETS NOT VIA AKT1 UP c2.JOHNSTONE PARVB TARGETS 1 UP c2.WP BARDETBIEDL SYNDROME c2.WF BARDETBIEDL STINDROME
c2.CERVERA SDHB TARGETS 1 DN
c2.WP ACTIVATION OF NLRP3 INFLAMMASOME BY SARSCOV2
c2.KEGG ALPHA LINOLENIC ACID METABOLISM
c2.EPPERT CE HSC LSC
c2.FOROUTAN PRODRANK TGFB EMT DN
c2.REACTOME NR1H2 NR1H3 REGULATE GENE EXPRESSION LINKED TO TRIGLYCERIDE LIPOLYSIS IN ADIPOSE c2.KEGG MEDICUS PATHOGEN HPV E7 TO CELL CYCLE G1 S c2.ONO AML1 TARGETS UP c2.TAVOR CEBPA TARGETS DN c2.LE NEURONAL DIFFERENTIATION DN c2.REACTOME FGFR1B LIGAND BINDING AND ACTIVATION c2.ZWANG EGF PERSISTENTLY DN c2.WP CELL INTERACTIONS OF THE PANCREATIC CANCER MICROENVIRONMENT c2.WOO LIVER CANCER RECURRENCE DN c2.CHARAFE BREAST CANCER LUMINAL VS MESENCHYMAL UP c2.RICKMAN HEAD AND NECK CANCER B c2.BIOCARTA MITOCHONDRIA PATHWAY c2.BRUINS UVC RESPONSE MIDDLE c2.CROONQUIST IL6 DEPRIVATION DN c2.REACTOME TRNA PROCESSING IN THE MITOCHONDRION
c2.ONO FOXP3 TARGETS UP
c2.WP CANCER IMMUNOTHERAPY BY PD1 BLOCKADE c2.REACTOME PARACETAMOL ADME c2.REACTOME CHOLINE CATABOLISM c2.REACTOME BILE ACID AND BILE SALT METABOLISM c2.REACTOME TELOMERE C STRAND SYNTHESIS INITIATION c2.RAMJAUN APOPTOSIS BY TGFB1 VIA SMAD4 UP c2.KEGG GLYCOSYLPHOSPHATIDYLINOSITOL GPI ANCHOR BIOSYNTHESIS c2.KEGG TRYPTOPHAN METABOLISM c2.WP NANOPARTICLE TRIGGERED REGULATED NECROSIS c2.FARMER BREAST CANCER CLUSTER 7 c2.MCMURRAY TP53 HRAS COOPERATION RESPONSE DN c2.CREIGHTON ENDOCRINE THERAPY RESISTANCE 2 c2.VALK AML CLUSTER 1 c2.THUM MIR21 TARGETS HEART DISEASE DN c2.WP ALLOGRAFT REJECTION c2.BIOCARTA ACE2 PATHWAY c2.HUANG AML LSC47
c2.KEGG MEDICUS REFERENCE GPI ANCHOR BIOSYNTHESIS
c2.LEE LIVER CANCER MYC DN c2.WP GABA METABOLISM AKA GHB c2.YAMASHITA METHYLATED IN PROSTATE CANCER c2.WP METHYLATION PATHWAYS c2.BOSCO INTERFERON INDUCED ANTIVIRAL MODULE c2.MIKKELSEN MCV6 LCP WITH H3K4ME3 c2.WP TRANSCRIPTIONAL CASCADE REGULATING ADIPOGENESIS c2.WP TRANSCRIPTIONAL CASCADE REGULATING ADIPOGENESIS
c2.WARTERS IR RESPONSE 5GY
c2.SCIAN INVERSED TARGETS OF TP53 AND TP73 UP
c2.BIOCARTA NEUTROPHIL PATHWAY
c2.REACTOME ACROSOME REACTION AND SPERM OOCYTE MEMBRANE BINDING
c2.REACTOME ELEVATION OF CYTOSOLIC CA2 LEVELS
c2.KEGG MEDICUS REFERENCE PURINE SALVAGE PATHWAY HYPOXANTHINE GUANINE TO IMP GMP
c2.PARK TRETINOIN RESPONSE AND RARA PLZF FUSION
c2.LI ESTROGENE MCF7 E2 RESPONSE UP
c2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO P21 CELL CYCLE G1 S N00498 c2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO P21 CELL CYCLE G1 S N00498
c2.LOPES METHYLATED IN COLON CANCER UP
c2.WENG POR TARGETS LIVER DN c2.KEGG MEDICUS REFERENCE LONG PATCH BER c2.OSAWA TNF TARGETS c2.KEGG MEDICUS REFERENCE DNA END RESECTION AND RPA LOADING c2. SABATES COLORECTAL ADENOMA DN c2.FOROUTAN TGFB EMT DN c2.BOSCO EPITHELIAL DIFFERENTIATION MODULE c2.YAMASHITA LIVER CANCER WITH EPCAM DN c2.WP INFLAMMATORY RESPONSE PATHWAY c2.REACTOME SLC15A4 TASL DEPENDENT IRF5 ACTIVATION c2.WP TYPE I INTERFERON INDUCTION AND SIGNALING DURING SARSCOV2 INFECTION c2.WP MIRNA ROLE IN IMMUNE RESPONSE IN SEPSIS c2.ZHOU INFLAMMATORY RESPONSE LPS UP c2.WATANABE COLON CANCER MSI VS MSS DN c2.WAIANABE COLON CANCER MSI VS MSS DN
c2.CHYLA CBFA2T3 TARGETS DN
c2.KEGG MEDICUS PATHOGEN KSHV MIR2 TO CELL SURFACE MOLECULE ENDOCYTOSIS
c2.SMID BREAST CANCER RELAPSE IN LUNG DN
c2.REACTOME MOLYBDENUM COFACTOR BIOSYNTHESIS
c2.KONG E2F3 TARGETS
c2.PARK TRETINOIN RESPONSE
c2.WALLACE PROSTATE CANCER RACE UP
c2.REACTOME CLEC7A INFLAMMASOME PATHWAY c2.HATADA METHYLATED IN LUNG CANCER UP c2.GAVIN PDE3B TARGETS c2.REACTOME BIOTIN TRANSPORT AND METABOLISM c2.HAHTOLA SEZARY SYNDROM DN c2.REACTOME MISMATCH REPAIR c2.WP ONECARBON METABOLISM c2.PID IL12 2PATHWAY c2.GRANDVAUX IFN RESPONSE NOT VIA IRF3 c2.KEGG MEDICUS REFERENCE CROSSTALK BETWEEN EXTRINSIC AND INTRINSIC APOPTOTIC PATHWAYS c2.KIM RESPONSE TO TSA AND DECITABINE UP c2.WANG CLASSIC ADIPOGENIC TARGETS OF PPARG c2.REACTOME G1 S SPECIFIC TRANSCRIPTION c2.ZHOU INFLAMMATORY RESPONSE FIMA DN c2.WP MIRNAS INVOLVED IN DNA DAMAGE RESPONSE c2.BLANCO MELO COVID19 SARS COV 2 INFECTION A594 CELLS DN c2.WP DNA MISMATCH REPAIR c2.PETROVA PROX1 TARGETS UP c2.GOBERT OLIGODENDROCYTE DIFFERENTIATION UP c2.REACTOME DEFECTIVE FACTOR VIII CAUSES HEMOPHILIA A c2.SMID BREAST CANCER NORMAL LIKE UP c2.KEGG MEDICUS PATHOGEN EBV EBNA3C TO P27 CELL CYCLE G1 S N00264 c2.LIU TOPBP1 TARGETS c2.BIOCARTA PLK3 PATHWAY c2.WP PYRIMIDINE METABOLISM AND RELATED DISEASES c2.BROWNE INTERFERON RESPONSIVE GENES c2.REACTOME ALPHA OXIDATION OF PHYTANATE c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS GREY DN C2 BORCZLIK MALIGNANT MESOTHELIOMA c2.KEGG MEDICUS REFERENCE WNT5A ROR SIGNALING PATHWAY c2.MEBARKI HCC PROGENITOR FZD8CRD UP c2.REACTOME PLASMA LIPOPROTEIN REMODELING c2.SMID BREAST CANCER RELAPSE IN PLEURA DN c2.PASTURAL RIZ1 TARGETS UP c2.LUDWICZEK TREATING IRON OVERLOAD c2.RIZ ERYTHROID DIFFERENTIATION HEMGN c2.WAGNER APO2 SENSITIVITY c2.SHIPP DLBCL CURED VS FATAL UP c2.BASSO CD40 SIGNALING DN c2.ONO FOXP3 TARGETS DN c2.REACTOME CYTOSOLIC IRON SULFUR CLUSTER ASSEMBLY c2.LEIN CEREBELLUM MARKERS c2.ZHAN MULTIPLE MYELOMA CD1 UP c2.KEGG MEDICUS REFERENCE WNT SIGNALING PATHWAY c2.BLANCO MELO COVID19 SARS COV 2 LOW MOI INFECTION A594 ACE2 EXPRESSING CELLS UP c2.MAEKAWA ATF2 TARGETS c2.BLANCO MELO BRONCHIAL EPITHELIAL CELLS INFLUENZA A INFECTION DN c2.KEGG MEDICUS REFERENCE MANNOSE TYPE O GLYCAN BIOSYNTHESIS POMT TO POMK c2.SLEBOS HEAD AND NECK CANCER WITH HPV UP c2.LEIN CHOROID PLEXUS MARKERS c2.REACTOME DISEASES OF MISMATCH REPAIR MMR c2.WP GLP1 FROM INTESTINE AND PANCREAS AND ROLE IN GLUCOSE HOMEOSTASIS c2.KIM LIVER CANCER POOR SURVIVAL DN c2.OHGUCHI LIVER HNF4A TARGETS UP c2.SA MMP CYTOKINE CONNECTION c2.KALMA E2F1 TARGETS c2.REACTOME PHASE I FUNCTIONALIZATION OF COMPOUNDS c2.LEE DOUBLE POLAR THYMOCYTE c2.SHANK TAL1 TARGETS DN c2.REACTOME LAGGING STRAND SYNTHESIS c2.REACTOME POU5F1 OCT4 SOX2 NANOG ACTIVATE GENES RELATED TO PROLIFERATION c2.REACTOME ASSEMBLY OF ACTIVE LPL AND LIPC LIPASE COMPLEXES c2.WP PHOSPHODIESTERASES IN NEURONAL FUNCTION c2.REACTOME SYNTHESIS OF DIPHTHAMIDE EEF2
c2.SMID BREAST CANCER RELAPSE IN BONE UP
c2.WP SARSCOV2 MITOCHONDRIAL CHRONIC OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION c2.KEGG MEDICUS VARIANT LOSS OF CDKN1B TO P27 CELL CYCLE G1 S c2.REACTOME METABOLISM OF WATER SOLUBLE VITAMINS AND COFACTORS c2.REACTOME HDL CLEARANCE c2.REACTOME SIGNALING BY GPCR c2.WP SULINDAC METABOLIC PATHWAY c2.KEGG MEDICUS REFERENCE CYTOKINE JAK STAT SIGNALING PATHWAY c2.ZWANG DOWN BY 2ND EGF PULSE c2.MEISSNER NPC ICP WITH H3K4ME3 c2.WP 17Q12 COPY NUMBER VARIATION SYNDROME c2.REACTOME O LINKED GLYCOSYLATION c2.BIOCARTA RACC PATHWAY c2.KEGG DNA REPLICATION c2.WP INTERACTIONS OF NATURAL KILLER CELLS IN PANCREATIC CANCER c2.KEGG MEDICUS REFERENCE MISMATCH REPAIR c2.HUI MAPK14 TARGETS UP c2.GAL LEUKEMIC STEM CELL DN c2.KASLER HDAC7 TARGETS 2 UP c2.HSIAO LIVER SPECIFIC GENES c2.KEGG MEDICUS VARIANT PAX8 PPARG FUSION TO PPARG MEDIATED TRANSCRIPTION c2.ZHOU CELL CYCLE GENES IN IR RESPONSE 6HR c2.RUAN RESPONSE TO TROGLITAZONE DN c2.WP METABOLIC PATHWAY OF LDL HDL AND TG INCLUDING DISEASES
c2.REACTOME G2 PHASE
c2.KEGG MEDICUS REFERENCE COHESIN ACETYLATION c2.BEIER GLIOMA STEM CELL UP c2.LIANG SILENCED BY METHYLATION 2 c2.SMID BREAST CANCER RELAPSE IN LIVER DN c2.REACTOME POLYMERASE SWITCHING c2.WP LEUKOTRIENE METABOLIC PATHWAY c2.FIGUEROA AML METHYLATION CLUSTER 4 DN c2.HANSON HRAS SIGNALING VIA NFKB c2.KEGG MEDICUS VARIANT LRP6 OVEREXPRESSION TO WNT SIGNALING PATHWAY c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 4 C2.REACTOME EGFR INTERACTS WITH PHOSPHOLIPASE C GAMMA C2.WP METHIONINE METABOLISM LEADING TO SULFUR AMINO ACIDS AND RELATED DISORDERS c2.WP PURINERGIC SIGNALING c2.WP HORMONAL CONTROL OF PUBERTAL GROWTH SPURT
c2.REACTOME POLO LIKE KINASE MEDIATED EVENTS c2.SCHLESINGER METHYLATED DE NOVO IN CANCER c2.DAZARD UV RESPONSE CLUSTER G28 c2.MEISSNER BRAIN ICP WITH H3K4ME3 c2.REACTOME GENERATION OF SECOND MESSENGER MOLECULES c2.PID IL23 PATHWAY c2.SMIRNOV RESPONSE TO IR 6HR DN c2.MATZUK MEIOTIC AND DNA REPAIR
c2.WP OCTADECANOID FORMATION FROM LINOLEIC ACID
c2.REACTOME LYSOSPHINGOLIPID AND LPA RECEPTORS c2.SMID BREAST CANCER LUMINAL A UP c2.RICKMAN HEAD AND NECK CANCER A c2.SMIRNOV RESPONSE TO IR 2HR DN c2.MARIADASON RESPONSE TO BUTYRATE CURCUMIN SULINDAC TSA 8 c2.XU GH1 EXOGENOUS TARGETS UP c2.REACTOME TRNA MODIFICATION IN THE MITOCHONDRION c2.BLANCO MELO BRONCHIAL EPITHELIAL CELLS INFLUENZA A DEL NS1 INFECTION UP c2.DURAND STROMA NS UP c2.REACTOME RESOLUTION OF ABASIC SITES AP SITES c2.REACTOME SIALIC ACID METABOLISM c2.HOLLEMAN PREDNISOLONE RESISTANCE B ALL DN c2.HANN RESISTANCE TO BCL2 INHIBITOR DN c2.MIKKELSEN ES ICP WITH H3K4ME3 c2.JIANG MELANOMA TRM10 LAMINA PROPRIA c2.WP DNA REPAIR PATHWAYS FULL NETWORK c2.WP DNA REPAIR PAI HWAYS FULL NETWORK
c2.NOUZOVA METHYLATED IN APL
c2.VANDESLUIS COMMD1 TARGETS GROUP 3 UP
c2.DAWSON METHYLATED IN LYMPHOMA TCL1
c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 10D UP
c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 6HR UP
c2.REACTOME DISEASES ASSOCIATED WITH SURFACTANT METABOLISM c2.WP LUNG FIBROSIS c2.WEST ADRENOCORTICAL CARCINOMA VS ADENOMA UP c2.REACTOME SYNTHESIS OF KETONE BODIES c2.LIM MAMMARY STEM CELL DN c2.SMIRNOV CIRCULATING ENDOTHELIOCYTES IN CANCER DN c2.REACTOME TIGHT JUNCTION INTERACTIONS c2.WP SOMATIC SEX DETERMINATION c2.HINATA NFKB TARGETS KERATINOCYTE DN c2.MCMURRAY TP53 HRAS COOPERATION RESPONSE UP c2.WP PATHWAYS OF NUCLEIC ACID METABOLISM AND INNATE IMMUNE SENSING c2.WP SEROTONIN AND ANXIETY c2.ISHIKAWA STING SIGNALING c2.WHITFIELD CELL CYCLE LITERATURE c2.REACTOME COMPLEMENT CASCADE c2.OKAWA NEUROBLASTOMA 1P36 31 DELETION c2.REACTOME DEFECTS IN VITAMIN AND COFACTOR METABOLISM c2.JIANG MELANOMA TRM11 CD8 c2.KEGG MEDICUS REFERENCE ORIGIN UNWINDING AND ELONGATION c2.ZHAN MULTIPLE MYELOMA DN c2.KEGG PANTOTHENATE AND COA BIOSYNTHESIS c2.REACTOME HDR THROUGH MMEJ ALT NHEJ c2.SHETH LIVER CANCER VS TXNIP LOSS PAM5 c2.REACTOME ACYL CHAIN REMODELLING OF PG c2.CAIRO HEPATOBLASTOMA DN c2.REACTOME TRANSPORT OF BILE SALTS AND ORGANIC ACIDS METAL IONS AND AMINE COMPOUNDS c2.HOLLERN MICROACINAR BREAST TUMOR UP c2.WP GLYCINE METABOLISM INCLUDING IMDS c2.SMID BREAST CANCER RELAPSE IN BRAIN UP c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 29 c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 29
c2.STREICHER LSM1 TARGETS DN
c2.REACTOME TELOMERE C STRAND LAGGING STRAND SYNTHESIS
c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 8D UP
c2.REACTOME POLYMERASE SWITCHING ON THE C STRAND OF THE TELOMERE
c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 16D UP
c2.BLANCO MELO HUMAN PARAINFLUENZA VIRUS 3 INFECTION A594 CELLS UP c2.LI ESTROGENE EARLY E2 RESPONSE UP c2.FURUKAWA DUSP6 TARGETS PCI35 DN
c2.FURUKAWA DUSP6 TARGETS PCI35 DN
c2.PID INTEGRIN2 PATHWAY
c2.WP GENE REGULATORY NETWORK MODELING SOMITOGENESIS
c2.KEGG O GLYCAN BIOSYNTHESIS
c2.FLORIO NEOCORTEX BASAL RADIAL GLIA DN c2.BLANCO MELO RESPIRATORY SYNCYTIAL VIRUS INFECTION A594 CELLS UP c2.REACTOME PHOSPHORYLATION OF EMI1 c2.WP VITAMIN B6DEPENDENT AND RESPONSIVE DISORDERS c2.WP AMINO ACID TRANSPORT DEFECTS IEMS
c2.WP AMINO ACID TRANSPORT DEFECTS IEMS
c2.SHARMA PILOCYTIC ASTROCYTOMA LOCATION UP
c2.REACTOME SODIUM PROTON EXCHANGERS
c2.KEGG MEDICUS REFERENCE LESION BYPASS BY TLS AND DSB FORMATION
c2.KEGG MEDICUS REFERENCE RTK PLCG ITPR SIGNALING PATHWAY
c2.PHESSE TARGETS OF APC AND MBD2 UP c2.PID WNT SIGNALING PATHWAY c2.REACTOME FANCONI ANEMIA PATHWAY c2.FURUKAWA DUSP6 TARGETS PCI35 UP c2.FORKAWA DOSF6 TARGETS FCISO OF C2.ONDER CDH1 TARGETS 2 DN C2.NADER CDH1 TARGETS 2 DN C2.KAUFFMANN MELANOMA RELAPSE UP C2.NABA MATRISOME ASSOCIATED C2.KEGG MEDICUS REFERENCE TCR PLCG ITPR SIGNALING PATHWAY C2.MIKKELSEN MCV6 ICP WITH H3K4ME3 AND H3K27ME3 C2.WP GANGLIO SPHINGOLIPID METABOLISM patho_cat_name Nerve sheath tumors c2.CHENG TAF7L TARGETS c2.REACTOME ERBB2 REGULATES CELL MOTILITY Spindle and epithelioid tumors ಬ c2.JOHANSSON BRAIN CANCER EARLY VS LATE UP Gliomas c2.REACTOME HEME DEGRADATION
c2.REACTOME ACTIVATION OF THE PRE REPLICATIVE COMPLEX c2.ZHANG INTERFERON RESPONSE Glioneuronal tumors c2.KEGG MEDICUS REFERENCE DNA REPLICATION LICENSING
c2.KEGG AMINOACYL TRNA BIOSYNTHESIS
c2.KEGG AMINOACYL TRNA BIOSYNTHESIS
c2.REACTOME OLFACTORY SIGNALING PATHWAY
c2.WP CELL DIFFERENTIATION INDEX
c2.REACTOME LEUKOTRIENE RECEPTORS c2.YEGNASUBRAMANIAN PROSTATE CANCER
c2.CHEOK RESPONSE TO MERCAPTOPURINE AND LD MTX DN
c2.BYSTRYKH HEMATOPOIESIS STEM CELL FLI1
c2.TESAR JAK TARGETS MOUSE ES D3 DN
c2.MCBRYAN TERMINAL END BUD UP c2.DODD NASOPHARYNGEAL CARCINOMA DN c2.KEGG MEDICUS REFERENCE BASE EXCISION AND STRAND CLEAVAGE BY NEIL GLYCOSYLASE c2.WANG MLL TARGETS c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS PINK DN c2.REACTOME CASPASE ACTIVATION VIA EXTRINSIC APOPTOTIC SIGNALLING PATHWAY c2.REACTOME PROCESSIVE SYNTHESIS ON THE LAGGING STRAND c2.CUI TCF21 TARGETS DN c2.MEISSNER ES ICP WITH H3K4ME3 c2.GENTLES LEUKEMIC STEM CELL DN c2.WP VITAMIN A AND CAROTENOID METABOLISM
c2.SEKI INFLAMMATORY RESPONSE LPS UP
c2.REACTOME SIGNALLING TO P38 VIA RIT AND RIN
c2.REACTOME SPECIFICATION OF PRIMORDIAL GERM CELLS c2.JAEGER METASTASIS DN
c2.KEGG MEDICUS VARIANT NOTCH OVEREXPRESSION TO NOTCH SIGNALING PATHWAY
c2.POOLA INVASIVE BREAST CANCER UP
c2.REACTOME PHOSPHATE BOND HYDROLYSIS BY NTPDASE PROTEINS
c2.REACTOME WNT LIGAND BIOGENESIS AND TRAFFICKING c2.BOYAULT LIVER CANCER SUBCLASS G123 DN c2.WP CEREBRAL ORGANIC ACIDURIAS INCLUDING DISEASES c2.WP SEROTONIN AND ANXIETYRELATED EVENTS c2.KORKOLA YOLK SAC TUMOR
c2.WP KYNURENINE PATHWAY AND LINKS TO CELL SENESCENCE
c2.REACTOME ACTIVATION OF ATR IN RESPONSE TO REPLICATION STRESS c2.MUELLER METHYLATED IN GLIOBLASTOMA

c2.WUELLER METHYLATED IN GLIOBLASTOMA

c3.WUELLER METHYLATED IN GLIOBLASTOMA

c4.WUELLER METHYLATED IN GLIOBLASTOMA

c5.WUELLER METHYLATED IN GLIOBLASTOMA

c6.WUELLER METHYLATED IN GLIOBLASTOMA

c7.WUELLER METHYLA c2.KEGG DRUG METABOLISM OTHER ENZYMES c2.KEGG NICOTINATE AND NICOTINAMIDE METABOLISM c2.REACTOME MRNA EDITING c2.CHIANG LIVER CANCER SUBCLASS CTNNB1 UP
c2.PYEON CANCER HEAD AND NECK VS CERVICAL DN
c2.REACTOME DOPAMINE CLEARANCE FROM THE SYNAPTIC CLEFT c2.SABATES COLORECTAL ADENOMA UP c2.REACTOME VITAMIN B2 RIBOFLAVIN METABOLISM c2.MEBARKI HCC PROGENITOR FZD8CRD DN c2.BIOCARTA HSP27 PATHWAY c2.HESSON TUMOR SUPPRESSOR CLUSTER 3P21 3 c2.WP MONOAMINE TRANSPORT c2.MADAN DPPA4 TARGETS c2.BIOCARTA CTLA4 PATHWAY c2.WP ATR SIGNALING c2.FOSTER KDM1A TARGETS UP c2.VECCHI GASTRIC CANCER ADVANCED VS EARLY DN c2.WP BIOMARKERS FOR UREA CYCLE DISORDERS c2.WATANABE ULCERATIVE COLITIS WITH CANCER DN c2.KEGG MEDICUS REFERENCE BREAK INDUCED REPLICATION c2.CERIBELLI GENES INACTIVE AND BOUND BY NFY c2.REACTOME VEGF LIGAND RECEPTOR INTERACTIONS c2.KEGG MEDICUS VARIANT AMPLIFIED REL TO TRANSCRIPTION
c2.BIOCARTA VOBESITY PATHWAY
c2.ALTEMEIER RESPONSE TO LPS WITH MECHANICAL VENTILATION
c2.KEGG GLYCINE SERINE AND THREONINE METABOLISM c2.REACTOME PURINE SALVAGE c2.LY AGING MIDDLE UP
c2.WAKASUGI HAVE ZNF143 BINDING SITES
c2.ZHOU PANCREATIC EXOCRINE PROGENITOR
c2.NIKOLSKY BREAST CANCER 20P13 AMPLICON
c2.REACTOME DISEASES OF IMMUNE SYSTEM c2.REACTOME UBIQUINOL BIOSYNTHESIS c2.RIZ ERYTHROID DIFFERENTIATION APOBEC2 c2.LI ESTROGENE META E2 RESPONSE UP c2.LINDGREN BLADDER CANCER CLUSTER 2A UP c2.GRAHAM NORMAL QUIESCENT VS NORMAL DIVIDING DN c2.KEGG MEDICUS REFERENCE II BLOOD GROUP ANTIGEN BIOSYNTHESIS c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 3D DN c2.REACTOME VITAMIN D CALCIFEROL METABOLISM c2.BIOCARTA FIBRINOLYSIS PATHWAY c2.REACTOME DNA STRAND ELONGATION c2.REACTOME HDR THROUGH HOMOLOGOUS RECOMBINATION HRR
c2.WP MACROPHAGE MARKERS
c2.CHARAFE BREAST CANCER BASAL VS MESENCHYMAL UP c2.KEGG BASAL CELL CARCINOMA c2.KEGG GLYCOSPHINGOLIPID BIOSYNTHESIS LACTO AND NEOLACTO SERIES c2.TANAKA METHYLATED IN ESOPHAGEAL CARCINOMA c2.WP RETINOL METABOLISM c2.WP GDNFRET SIGNALING AXIS c2.WP RAS AND BRADYKININ PATHWAYS IN COVID19 c2.HOLLERN SQUAMOUS BREAST TUMOR c2.KEGG MEDICUS REFERENCE HORMONE LIKE CYTOKINE TO JAK STAT SIGNALING PATHWAY c2.LU TUMOR VASCULATURE DN c2.NIKOLSKY BREAST CANCER 1Q21 AMPLICON c2.WANG THOC1 TARGETS UP c2.PIEPOLI LGI1 TARGETS DN c2.WP POSTCOVID NEUROINFLAMMATION c2.FEKIR HEPARG SIDE POP VS HEPARG DN c2.MIKKELSEN PLURIPOTENT STATE UP c2.KEGG MEDICUS REFERENCE PRE IC FORMATION c2.FARMER BREAST CANCER CLUSTER 2 c2.BLANCO MELO COVID19 SARS COV 2 INFECTION A594 CELLS UP c2.WP DISORDERS OF BILE ACID SYNTHESIS AND BILIARY TRANSPORT c2.NOUSHMEHR GBM SILENCED BY METHYLATION c2.KORKOLA EMBRYONIC CARCINOMA VS SEMINOMA DN c2.KEGG MEDICUS REFERENCE BASE EXCISION AND STRAND CLEAVAGE BY MONOFUNCTIONAL GLYCOSYLASE c2.WP GPCRS CLASS C METABOTROPIC GLUTAMATE PHEROMONE c2.NAKAYAMA SOFT TISSUE TUMORS PCA2 DN c2.REACTOME SIGNALING BY LRP5 MUTANTS c2.BLANCO MELO COVID19 SARS COV 2 INFECTION CALU3 CELLS UP c2.KEGG MEDICUS PATHOGEN EBV EBNA3C TO P27 CELL CYCLE G1 S N00482 c2.REACTOME NGF INDEPENDANT TRKA ACTIVATION c2.KEGG COMPLEMENT AND COAGULATION CASCADES c2.REACTOME THE CANONICAL RETINOID CYCLE IN RODS TWILIGHT VISION c2.REACTOME ASPIRIN ADME c2.LIU CDX2 TARGETS DN c2.ZHENG IL22 SIGNALING UP c2.KANG DOXORUBICIN RESISTANCE UP c2.WP VITAMIN K METABOLISM AND ACTIVATION OF DEPENDENT PROTEINS c2.LI ADIPOGENESIS BY ACTIVATED PPARG c2.REACTOME BLOOD GROUP SYSTEMS BIOSYNTHESIS c2.SEAVEY EPITHELIOID HEMANGIOENDOTHELIOMA c2.KUNINGER IGF1 VS PDGFB TARGETS UP c2.MOLENAAR TARGETS OF CCND1 AND CDK4 DN c2.GHANDHI DIRECT IRRADIATION UP c2.KEGG BASE EXCISION REPAIR c2.REACTOME CGMP EFFECTS c2.CHEN ETV5 TARGETS TESTIS
c2.WP LTF DANGER SIGNAL RESPONSE PATHWAY
c2.WP 70XOC AND 7BETAHC PATHWAYS c2.KEGG ONE CARBON POOL BY FOLATE c2.WORSCHECH TUMOR EVASION AND TOLEROGENICITY UP c2.YANG BCL3 TARGETS DN c2.KEGG MEDICUS ENV FACTOR NNK TO DNA ADDUCTS c2.WP STRIATED MUSCLE CONTRACTION PATHWAY c2.REACTOME PURINE CATABOLISM c2.KEGG METABOLISM OF XENOBIOTICS BY CYTOCHROME P450 c2.KUMAMOTO RESPONSE TO NUTLIN 3A DN c2.WP METAPATHWAY BIOTRANSFORMATION PHASE I AND II c2.REACTOME ACYL CHAIN REMODELLING OF PC c2.MILICIC FAMILIAL ADENOMATOUS POLYPOSIS DN c2.REACTOME COMMON PATHWAY OF FIBRIN CLOT FORMATION c2.SHARMA ASTROCYTOMA WITH NF1 SYNDROM c2.REACTOME SURFACTANT METABOLISM c2.WP IRINOTECAN PATHWAY c2.KEGG RETINOL METABOLISM c2.WP DISORDERS OF FOLATE METABOLISM AND TRANSPORT c2.REACTOME NITRIC OXIDE STIMULATES GUANYLATE CYCLASE c2.REACTOME SYNTHESIS OF LEUKOTRIENES LT AND EOXINS EX c2.BLANCO MELO COVID19 BRONCHIAL EPITHELIAL CELLS SARS COV 2 INFECTION UP c2.REACTOME COBALAMIN CBL VITAMIN B12 TRANSPORT AND METABOLISM c2.LY AGING MIDDLE DN c2.REACTOME INTERLEUKIN 1 PROCESSING c2.REACTOME NUCLEOTIDE SALVAGE c2.MISHRA CARCINOMA ASSOCIATED FIBROBLAST DN c2.HEDVAT ELF4 TARGETS UP c2.KRISHNAN FURIN TARGETS DN c2.VANLOO SP3 TARGETS UP c2.REACTOME SYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL GPI c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 1 c2.REACTOME FGFRL1 MODULATION OF FGFR1 SIGNALING c2.PEDERSEN METASTASIS BY ERBB2 ISOFORM 6 c2.REACTOME NICOTINAMIDE SALVAGING ION TO TRANSCRIPTIONAL ACTIVATION c2.MOROSETTI FACIOSCAPULOHUMERAL MUSCULAR DISTROPHY DN c2.LU TUMOR ENDOTHELIAL MARKERS DN c2.ABBUD LIF SIGNALING 2 DN c2.REACTOME COBALAMIN CBL METABOLISM c2.BIOCARTA WNT LRP6 PATHWAY c2.CHIANG LIVER CANCER SUBCLASS POLYSOMY7 UP c2.FIGUEROA AML METHYLATION CLUSTER 6 DN c2.KIM ALL DISORDERS CALB1 CORR DN c2.REACTOME NUCLEOTIDE CATABOLISM c2.WP BASE EXCISION REPAIR c2.KOHOUTEK CCNT2 TARGETS c2.PID ERBB NETWORK PATHWAY c2.REACTOME HYALURONAN BIOSYNTHESIS AND EXPORT c2.KEGG MEDICUS REFERENCE HOMOLOGOUS RECOMBINATION IN ICLR c2.WP PROSTAGLANDIN SYNTHESIS AND REGULATION c2.ROETH TERT TARGETS DN c2.REACTOME PI3K EVENTS IN ERBB4 SIGNALING c2.REACTOME RA BIOSYNTHESIS PATHWAY c2.SERVITJA LIVER HNF1A TARGETS DN c2.WP FLUOROPYRIMIDINE ACTIVITY c2.MARSON FOXP3 CORE DIRECT TARGETS c2.WP GPCRS CLASS B SECRETINLIKE c2.WP CLASSICAL PATHWAY OF STEROIDOGENESIS WITH GLUCOCORTICOID AND MINERALOCORTICOID METABOLISM c2.KEGG MEDICUS PATHOGEN HIV VPR TO WEE1 CELL CYCLE G2M c2.REACTOME HDR THROUGH SINGLE STRAND ANNEALING SSA c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS TURQUOISE DN c2.KLEIN TARGETS OF BCR ABL1 FUSION c2.PLASARI NFIC TARGETS BASAL UP c2.REACTOME CHYLOMICRON REMODELING
c2.KEGG MEDICUS REFERENCE NLRP3 INFLAMMASOME SIGNALING PATHWAY
c2.WP FARNESOID X RECEPTOR PATHWAY
c2.REACTOME MITOCHONDRIAL TRNA AMINOACYLATION c2.REACTOME G2 M DNA REPLICATION CHECKPOINT c2.CHEMELLO SOLEUS VS EDL MYOFIBERS DN c2.HOFFMAN CLOCK TARGETS DN c2.WP CYSTEINE AND METHIONINE CATABOLISM
c2.KEGG MEDICUS VARIANT AMPLIFIED CONE TO CELL CYCLE G1 S
c2.REACTOME RUNX1 AND FOXP3 CONTROL THE DEVELOPMENT OF REGULATORY T LYMPHOCYTES TREGS c2.CLIMENT BREAST CANCER COPY NUMBER DN c2.REACTOME NICOTINATE METABOLISM c2.REACTOME CLASS B 2 SECRETIN FAMILY RECEPTORS c2.ROETH TERT TARGETS UP c2.REACTOME DEFECTS IN COBALAMIN B12 METABOLISM c2.REACTOME SYNTHESIS OF 16 20 HYDROXYEICOSATETRAENOIC ACIDS HETE c2.KEGG MEDICUS REFERENCE OKAZAKI FRAGMENT MATURATION c2.MISIAK ANAPLASTIC THYROID CARCINOMA UP c2.REACTOME POST TRANSLATIONAL MODIFICATION SYNTHESIS OF GPI ANCHORED PROTEINS c2.WP SOMITOGENESIS IN THE CONTEXT OF SPONDYLOCOSTAL DYSOSTOSIS c2.LEE EARLY T LYMPHOCYTE UP c2.MIKKELSEN IPS LCP WITH H3K4ME3
c2.MIKKELSEN ES HCP WITH H3 UNMETHYLATED
c2.WP EXTRAFOLLICULAR AND FOLLICULAR B CELL ACTIVATION BY SARSCOV2 c2.REACTOME RECYCLING OF BILE ACIDS AND SALTS c2.REACTOME SIGNALING BY RNF43 MUTANTS c2.EGUCHI CELL CYCLE RB1 TARGETS c2.KEGG MEDICUS REFERENCE LECTIN PATHWAY OF COMPLEMENT CASCADE C4 C2 TO C3 CONVERTASE FORMATION c2.GHANDHI BYSTANDER IRRADIATION UP c2.SEKI INFLAMMATORY RESPONSE LPS DN c2.REACTOME NEGATIVE REGULATION OF TCF DEPENDENT SIGNALING BY WNT LIGAND ANTAGONISTS c2.KEGG RENIN ANGIOTENSIN SYSTEM c2.LEE LIVER CANCER MYC TGFA DN c2.REACTOME DNA REPLICATION INITIATION c2.REACTOME P2Y RECEPTORS c2.DUTERTRE ESTRADIOL RESPONSE 24HR UP c2.BENPORATH EED TARGETS c2.SEMBA FHIT TARGETS DN c2.COLDREN GEFITINIB RESISTANCE DN c2.CARRILLOREIXACH HEPATOBLASTOMA VS NORMAL DN c2.WP GAMMAGLUTAMYL CYCLE FOR THE BIOSYNTHESIS AND DEGRADATION OF GLUTATHIONE INCLUDING DISEASES c2.WEBER METHYLATED IN COLON CANCER c2.KEGG ARACHIDONIC ACID METABOLISM c2.GAVIN IL2 RESPONSIVE FOXP3 TARGETS UP c2.LIM MAMMARY LUMINAL MATURE UP c2.PID DNA PK PATHWAY c2.KEGG MEDICUS REFERENCE REGULATION OF FIBRINOLYTIC SYSTEM C1INH c2.REACTOME PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING **(0)** c2.KEGG MEDICUS REFERENCE TLR7 9 IRF7 SIGNALING PATHWAY c2.REACTOME O LINKED GLYCOSYLATION OF MUCINS c2.TONKS TARGETS OF RUNX1 RUNX1T1 FUSION GRANULOCYTE DN c2.HOLLERN PAPILLARY BREAST TUMOR c2.UROSEVIC RESPONSE TO IMIQUIMOD c2.SHEN SMARCA2 TARGETS DN c2.WP OXIDATION BY CYTOCHROME P450 c2.SU PLACENTA c2.DIERICK SEROTONIN FUNCTION GENES c2.GAVIN FOXP3 TARGETS CLUSTER P6 c2.MEISSNER NPC HCP WITH H3K4ME2 c2.KEGG MEDICUS VARIANT AML1 ETO FUSION TO PU.1 MEDIATED TRANSCRIPTION c2.LIM MAMMARY LUMINAL PROGENITOR UP c2.REACTOME PYRIMIDINE SALVAGE c2.REACTOME RETINOID CYCLE DISEASE EVENTS c2.LI ESTROGENE NON MCF7 T47D E2 RESPONSE UP c2.KEGG TYROSINE METABOLISM c2.WP BLOOD CLOTTING CASCADE c2.BENPORATH ES 2
c2.REACTOME GLI PROTEINS BIND PROMOTERS OF HH RESPONSIVE GENES TO PROMOTE TRANSCRIPTION c2.MEISSNER BRAIN HCP WITH H3K4ME3 AND H3K27ME3 c2.KEGG MEDICUS REFERENCE HOMOLOGOUS RECOMBINATION c2.WP LUNG PATHOLOGY OF COVID19 c2.REACTOME APEX1 INDEPENDENT RESOLUTION OF AP SITES VIA THE SINGLE NUCLEOTIDE REPLACEMENT PATHWAY c2.REACTOME GRB7 EVENTS IN ERBB2 SIGNALING c2.FINAK BREAST CANCER SDPP SIGNATURE c2.REACTOME TP53 REGULATES TRANSCRIPTION OF CASPASE ACTIVATORS AND CASPASES c2.REACTOME SYNTHESIS OF EPOXY EET AND DIHYDROXYEICOSATRIENOIC ACIDS DHET c2.KEGG MEDICUS PATHOGEN EBV EBNA3C TO CELL CYCLE G1 S N00484 c2.REACTOME THE ACTIVATION OF ARYLSULFATASES c2.HASEGAWA TUMORIGENESIS BY RET C634R c2.PID FANCONI PATHWAY c2.REACTOME PHASE 2 PLATEAU PHASE c2.SMID BREAST CANCER NORMAL LIKE DN c2.CADWELL ATG16L1 TARGETS UP c2.CHIANG LIVER CANCER SUBCLASS PROLIFERATION DN c2.SERVITJA ISLET HNF1A TARGETS DN c2.NADERI BREAST CANCER PROGNOSIS UP c2.KORKOLA EMBRYONAL CARCINOMA DN c2.KORKOLA SEMINOMA DN c2.XU AKT1 TARGETS 48HR c2.KEGG MEDICUS REFERENCE HEDGEHOG SIGNALING PATHWAY PTCH CORECEPTOR c2.SABATES COLORECTAL ADENOMA SIZE DN c2.WANG METASTASIS OF BREAST CANCER c2.KEGG MEDICUS REFERENCE EXTRINSIC APOPTOTIC PATHWAY c2.IGLESIAS E2F TARGETS DN c2.BIERIE INFLAMMATORY RESPONSE TGFB1 000000 c2.WP FATTY ACID OMEGAOXIDATION (00)10 c2.REACTOME ACYL CHAIN REMODELLING OF PE c2.WP PLURIPOTENT STEM CELL DIFFERENTIATION PATHWAY c2.SCHMIDT POR TARGETS IN LIMB BUD DN c2.REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL c2.LEE LIVER CANCER DENA DN c2.ZWANG TRANSIENTLY UP BY 2ND EGF PULSE ONLY c2.ZHAN MULTIPLE MYELOMA PR UP c2.LEE LIVER CANCER MYC E2F1 DN 00 | job c2.LI ESTROGENE NON MCF7 T47D E2 RESPONSE DN c2.KEGG MEDICUS REFERENCE WEE1 CELL CYCLE G2 M c2.REGG MEDICUS REFERENCE WEET GELL CITCLE GZ IM c2.WP SLEEP REGULATION c2.REACTOME EPITHELIAL MESENCHYMAL TRANSITION EMT DURING GASTRULATION c2.KEGG MEDICUS PATHOGEN HPV E7 TO P27 CELL CYCLE G1 S c2.HATADA METHYLATED IN LUNG CANCER DN c2.HATADA METHYLATED IN LONG CANCER DN
c2.OSADA ASCL1 TARGETS UP
c2.KEGG MEDICUS REFERENCE ORGANIZATION OF THE OUTER KINETOCHORE
c2.VILIMAS NOTCH1 TARGETS UP
c2.LI ESTROGENE LATE E2 RESPONSE UP
c2.REACTOME VITAMIN B1 THIAMIN METABOLISM
c2.REACTOME INTERLEUKIN 2 SIGNALING c2.REACTOME HYDROLYSIS OF LPC c2.WP DISORDERS OF GALACTOSE METABOLISM c2.REACTOME STRIATED MUSCLE CONTRACTION c2.SCHLESINGER H3K27ME3 IN NORMAL AND METHYLATED IN CANCER c2.KEGG MEDICUS REFERENCE NUCLEAR INITIATED PROGESTERONE SIGNALING PATHWAY c2.REACTOME DECTIN 2 FAMILY c2.BENPORATH SUZ12 TARGETS c2.BIOCARTA SODD PATHWAY c2.GRAHAM CML QUIESCENT VS CML DIVIDING DN c2.KONDO PROSTATE CANCER WITH H3K27ME3
c2.REACTOME RRNA PROCESSING IN THE MITOCHONDRION
c2.KEGG MEDICUS REFERENCE RECRUITMENT AND FORMATION OF THE MCC c2.MARTINELLI IMMATURE NEUTROPHIL DN c2.TSUTSUMI FBXW8 TARGETS c2.KEGG MEDICUS REFERENCE REGULATION OF EXTRINSIC APOPTOTIC PATHWAY XIAP c2.KEGG MEDICUS REFERENCE REGULATION OF COMPLEMENT CASCADE MAC INHIBITION c2.DOANE BREAST CANCER ESR1 UP c2.REACTOME VLDL ASSEMBLY c2.ZHANG GATA6 TARGETS UP c2.KEGG MEDICUS REFERENCE CA2 ENTRY VOLTAGE GATED CA2 CHANNEL c2.LOPEZ MESOTELIOMA SURVIVAL TIME DN c2.BLANCO MELO SARS COV 1 INFECTION MCR5 CELLS DN c2.BLANCO MELO MERS COV INFECTION MCR5 CELLS UP c2.KEGG MEDICUS REFERENCE HEDGEHOG SIGNALING PATHWAY c2.WP MAJOR RECEPTORS TARGETED BY EPINEPHRINE AND NOREPINEPHRINE c2.KEGG MEDICUS REFERENCE IL2 FAMILY TO JAK STAT SIGNALING PATHWAY c2.KEGG DRUG METABOLISM CYTOCHROME P450 c2.REACTOME LIGAND RECEPTOR INTERACTIONS c2.KEGG MEDICUS REFERENCE RAD51 DSDNA DESTABILIZATION c2.WP IMMUNE INFILTRATION IN PANCREATIC CANCER c2.BIOCARTA NUCLEARRS PATHWAY c2.WP NUCLEAR RECEPTORS IN LIPID METABOLISM AND TOXICITY c2.PARK OSTEOBLAST DIFFERENTIATION BY PHENYLAMIL UP c2.REACTOME RELEASE OF HH NP FROM THE SECRETING CELL c2.WP EICOSANOID METABOLISM VIA LIPOOXYGENASES LOX c2.WP EICOSANOID ME IABOULISM VIA LIPOOXYGENASES LOX c2.WP T CELL MODULATION IN PANCREATIC CANCER c2.REACTOME GLUTATHIONE SYNTHESIS AND RECYCLING c2.WP ULCERATIVE COLITIS SIGNALING c2.KEGG MEDICUS PATHOGEN HTLV 1 P12 TO JAK STAT SIGNALING PATHWAY c2.REACTOME CYTOCHROME P450 ARRANGED BY SUBSTRATE TYPE c2.TESAR ALK AND JAK TARGETS MOUSE ES D4 UP 0000 c2.WP OSX AND MIRNAS IN TOOTH DEVELOPMENT Ф c2.REACTOME TERMINAL PATHWAY OF COMPLEMENT c2.WP INTERACTIONS BETWEEN IMMUNE CELLS AND MICRORNAS IN TUMOR MICROENVIRONMENT c2.REACTOME NUCLEOTIDE LIKE PURINERGIC RECEPTORS c2.REACTOME SENSORY PERCEPTION OF TASTE c2.ALONSO METASTASIS EMT DN c2.KEGG MEDICUS REFERENCE CD40 NFKB SIGNALING PATHWAY c2.RICKMAN HEAD AND NECK CANCER F c2.MAHADEVAN IMATINIB RESISTANCE DN c2.WP NICOTINE METABOLISM IN LIVER CELLS c2.KEGG HOMOLOGOUS RECOMBINATION c2.KEGG MEDICUS REFERENCE NOTCH MESP2 SIGNALING c2.WP EICOSANOID SYNTHESIS
c2.GUTIERREZ WALDENSTROEMS MACROGLOBULINEMIA 2
c2.BENPORATH ES WITH H3K27ME3 c2.BLANCO MELO SARS COV 1 INFECTION MCR5 CELLS UP c2.REACTOME METABOLISM OF FOLATE AND PTERINES c2.BOSCO TH1 CYTOTOXIC MODULE c2.REACTOME HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE c2.REACTOME FORMATION OF THE URETERIC BUD c2.WP EICOSANOID METABOLISM VIA CYCLOOXYGENASES COX c2.WP BIOSYNTHESIS AND REGENERATION OF TETRAHYDROBIOPTERIN AND CATABOLISM OF PHENYLALANINE c2.BIOCARTA ERYTH PATHWAY c2.REACTOME UNWINDING OF DNA c2.NOURUZI NEPC ASCL1 TARGETS c2.REACTOME BIOSYNTHESIS OF SPECIALIZED PRORESOLVING MEDIATORS SPMS c2.KEGG FOLATE BIOSYNTHESIS c2.KEGG MEDICUS REFERENCE MODIFYING OF CONDENSIN I SUBUNITS c2.LEE LIVER CANCER ACOX1 DN c2.REACTOME TERMINATION OF O GLYCAN BIOSYNTHESIS c2.WP VITAMIN B12 DISORDERS
c2.WP LIPID METABOLISM IN SENESCENT CELLS
c2.BLANCO MELO HUMAN PARAINFLUENZA VIRUS 3 INFECTION A594 CELLS DN c2.KEGG MEDICUS REFERENCE PRL JAK STAT SIGNALING PATHWAY c2.WP FTO OBESITY VARIANT MECHANISM c2.REACTOME DISEASES OF DNA REPAIR c2.WP PLATELETMEDIATED INTERACTIONS WITH VASCULAR AND CIRCULATING CELLS c2.PID RHODOPSIN PATHWAY c2.REACTOME PREGNENOLONE BIOSYNTHESIS c2.WP HOMOLOGOUS RECOMBINATION c2.FUJIWARA PARK2 IN LIVER CANCER DN c2.REACTOME NEUROTRANSMITTER CLEARANCE c2.LEE LIVER CANCER CIPROFIBRATE DN c2.KEGG MEDICUS REFERENCE NON HOMOLOGOUS END JOINING c2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX6 DN c2.KEGG MEDICUS REFERENCE CARDIAC TYPE VGCC RYR SIGNALING c2.REACTOME INTERLEUKIN 10 SIGNALING c2.IYENGAR RESPONSE TO ADIPOCYTE FACTORS c2.WP CYTOKINECYTOKINE RECEPTOR INTERACTION c2.SU PANCREAS c2.RICKMAN HEAD AND NECK CANCER C c2.WP MRNA VACCINE ACTIVATION OF DENDRITIC CELL AND INDUCTION OF IFN1 c2.REACTOME FGFR1 LIGAND BINDING AND ACTIVATION c2.MEBARKI HCC PROGENITOR WNT DN CTNNB1 DEPENDENT c2.KEGG MEDICUS REFERENCE TLR7 8 9 IRF5 SIGNALING PATHWAY c2.DESERT PERIPORTAL HEPATOCELLULAR CARCINOMA SUBCLASS UP c2.MARTENS TRETINOIN RESPONSE UP c2.REACTOME ELECTRIC TRANSMISSION ACROSS GAP JUNCTIONS c2.LI WILMS TUMOR
c2.YAUCH HEDGEHOG SIGNALING PARACRINE DN c2.KEGG MEDICUS REFERENCE CDC25 CELL CYCLE G2 M c2.KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION c2.KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION
c2.STAEGE EWING FAMILY TUMOR
c2.REACTOME PASSIVE TRANSPORT BY AQUAPORINS
c2.BLANCO MELO BETA INTERFERON TREATED BRONCHIAL EPITHELIAL CELLS DN
c2.REACTOME POTASSIUM CHANNELS
c2.REACTOME KIDNEY DEVELOPMENT
c2.KEGG MEDICUS PATHOGEN YERSINIA YOPH TO TCR NFAT SIGNALING PATHWAY
c2.REACTOME ACTIVATION OF TRKA RECEPTORS c2.NEACTOME ACTIVATION OF TRANSCRIPTIONAL REGULATION OF TESTIS DIFFERENTIATION

c2.WP FAMILIAL HYPERLIPIDEMIA TYPE 2

c2.REACTOME TRANSCRIPTIONAL REGULATION OF TESTIS DIFFERENTIATION

c2.SUMI HNF4A TARGETS

c2.REACTOME TRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL

c2.MIKKELSEN MEF ICP WITH H3K4ME3 AND H3K27ME3 c2.GAURNIER PSMD4 TARGETS C2.GAUKNIEK PSMIJ4 IARGE I3
C2.WONG ENDOMETRIAL CANCER LATE
C2.REACTOME UPTAKE OF DIETARY COBALAMINS INTO ENTEROCYTES
C2.REACTOME ACYL CHAIN REMODELLING OF PS
C2.REACTOME CALCITONIN LIKE LIGAND RECEPTORS
C2.MIKKELSEN ES ICP WITH H3K4ME3 AND ANALYME3
C2.COMERCIAN REPORTED AND COME AND ANALYMES AND ANALYMES AND ANALYMES AND COMERCIAN CO c2.MIKKELSEN ES ICP WITH H3K4ME3 AND H3K27ME3
c2.KEGG MEDICUS REFERENCE FANCONI ANEMIA PATHWAY
c2.REACTOME GDP FUCOSE BIOSYNTHESIS
c2.TESAR ALK TARGETS HUMAN ES 4D DN
c2.TESAR ALK TARGETS HUMAN ES 5D DN
c2.REACTOME REGULATION OF SIGNALING BY NODAL
c2.WP EDA SIGNALING IN HAIR FOLLICLE DEVELOPMENT
c2.MEBARKI HCC PROGENITOR WNT DN c2.ZHENG FOXP3 TARGETS IN T LYMPHOCYTE UP c2.MATZUK STEROIDOGENESIS c2.CAIRO HEPATOBLASTOMA POOR SURVIVAL c2.CARRILLOREIXACH HEPATOBLASTOMA VS NORMAL HYPERMETHYLATED AND DN c2.KEGG MEDICUS REFERENCE THE RIPKI SIGNALING PATHWAY c2.KEGG NON HOMOLOGOUS END JOINING C2.KEGG NON HOMOLOGOUS END JOINING
C2.SENGUPTA NASOPHARYNGEAL CARCINOMA DN
C2.REACTOME SIGNALING BY ACTIVATED POINT MUTANTS OF FGFR1
C2.WP HUNGER AND SATIETY
C2.WP NONHOMOLOGOUS END JOINING
C2.WONG ENDMETRIUM CANCER UP c2.SENGUPTA NASOPHARYNGEAL CARCINOMA WITH LMP1 DN c2.SALVADOR MARTIN PEDIATRIC TBD ANTI TNF THERAPY NONRESPONDER POST TREATMENT UP c2.BLANCO MELO COVID19 SARS COV 2 POS PATIENT LUNG TISSUE UP c2.MIKKELSEN ES ICP WITH H3K27ME3
c2.REACTOME TRAIL SIGNALING
c2.WP DEVELOPMENT AND HETEROGENEITY OF THE ILC FAMILY
c2.REACTOME PHOSPHOLIPASE C MEDIATED CASCADE FGF1 c2.KEGG MEDICUS REFERENCE NALP12 INFLAMMASOME SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE NLRP1 INFLAMMASOME SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE PYRIN INFLAMMASOME SIGNALING PATHWAY c2.REACTOME SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 24 HYDROXYCHOLESTEROL c2.WP VITAMIN D METABOLISM c2.MEISSNER NPC HCP WITH H3K4ME3 AND H3K27ME3 c2.MIKKELSEN NPC HCP WITH H3K4ME3 AND H3K27ME3 c2.BLANCO MELO BRONCHIAL EPITHELIAL CELLS INFLUENZA A DEL NS1 INFECTION DN c2.WUNDER INFLAMMATORY RESPONSE AND CHOLESTEROL DN c2.KEGG MEDICUS PATHOGEN SARS COV 2 S TO ANGII AT1R NOX2 SIGNALING PATHWAY c2.NAKAMURA ALVEOLAR EPITHELIUM c2.MIKKELSEN ES LCP WITH H3K4ME3 c2.MIKKELSEN IPS HCP WITH H3 UNMETHYLATED c2.MOSERLE IFNA RESPONSE c2.WP ASPIRIN AND MIRNAS c2.MEBARKI HCC PROGENITOR WNT DN CTNNB1 DEPENDENT BLOCKED BY FZD8CRC c2.WP EFFECT OF INTESTINAL MICROBIOME ON ANTICOAGULANT RESPONSE OF VITAMIN K ANTAGONISTS c2.WP HEMATOPOIETIC STEM CELL DIFFERENTIATION c2.MIKKELSEN IPS ICP WITH H3K4ME3 AND H327ME3 c2.REACTOME ORGANIC CATION TRANSPORT c2.WP CELLS AND MOLECULES INVOLVED IN LOCAL ACUTE INFLAMMATORY RESPONSE c2.OHGUCHI LIVER HNF4A TARGETS DN c2.LIEN BREAST CARCINOMA METAPLASTIC VS DUCTAL DN c2.MIKKELSEN MCV6 HCP WITH H3K27ME3 c2.REACTOME TRYPTOPHAN CATABOLISM c2 MILICIC FAMILIAL ADENOMATOUS POLYPOSIS UP c2.REACTOME METABOLISM OF STEROID HORMONES c2.SETLUR PROSTATE CANCER TMPRSS2 ERG FUSION DN c2.REACTOME FRUCTOSE METABOLISM c2.BIOCARTA LECTIN PATHWAY c2.REACTOME FLT3 SIGNALING THROUGH SRC FAMILY KINASES c2.WP SCFA AND SKELETAL MUSCLE SUBSTRATE METABOLISM c2.MEISSNER NPC HCP WITH H3 UNMETHYLATED c2.FINETTI BREAST CANCER KINOME GREEN c2.NIKOLSKY BREAST CANCER 1032 AMPLICON c2.REACTOME SPECIFICATION OF THE NEURAL PLATE BORDER -0.4-0.2 0.0 0.2 0.40.4-0.2 0.0 0.2 0.40.4-0.2 0.0 0.2 0.40.4-0.2 0.0 0.2 0.4 z_score